| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3874048 | The Journal of Urology | 2007 | 6 Pages |
Abstract
Multiple agents currently under development offer a promise of palliation and prolongation of survival above and beyond that of docetaxel. In the absence of guidance from randomized trials with regard to chemotherapy timing, and considering the modest effects of docetaxel on survival, decisions regarding choice of therapy (standard chemotherapy or experimental therapies) must be based on careful consideration of the functional status of each individual, presence of symptoms, comorbidities and overall therapeutic objectives.
Keywords
Cytotoxic T lymphocyte-associated antigen 4receptor activator of nuclear factor-κBCALGBCTLA4PSAET-1HSP90HDACProstate specific antigenAndrogenendothelin 1immunotherapyDrug therapyRankcancer and leukemia Group BVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)Prostatic neoplasmshistone deacetylaseHeat shock protein 90ProstateAndrogen ReceptorReceptors
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Gretchen A. Gignac, Michael J. Morris, Maha Hussain,